Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - dexamethasone, quantity: 0.5 mg/ml; framycetin sulfate, quantity: 5 mg/ml; gramicidin, quantity: 0.05 mg/ml - ear drops - excipient ingredients: phenethyl alcohol; polysorbate 80; citric acid monohydrate; sodium citrate dihydrate; lithium chloride; purified water; industrial methylated spirit; hydrochloric acid; sodium hydroxide - indications as at 5 october 2000: inflammatory and allergic conditions of the ear, e.g. otitis externa. eczema of the auditory meatus is often present and causes inflammation, exudation and pruritus, which are all rapidly relieved by dexamethasone. infection,often secondary to scratching, is generally due to staphylococci, e. coli, pseudomonas and proteus spp. which respond rapidly to framycetin.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 4 mg in 1 ml - - intravenous or intramuscular administration. when oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: endocrine disorders. primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is

United States - English - NLM (National Library of Medicine)

vedco, inc. - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 2 mg in 1 ml - dexamethasone injection 2 mg/ml is indcated for  the treatment of primary bovine ketosis an as an anti-inflammatory agent in the bovine and equine. as supportive therapy, dexamethasone injection 2 mg/ml may be used in the management of vairious rheumatic, allergic dermatologic, and other diseases known to be responsive to anti-inflammatory corticosteroids.  dexamethasone injection 2 mg/ml may be used intravenously as supportive therapy when an immeidate hormonal response is required. bovine ketosis dexamethasone injection 2 mg/ml is offered for the treatment of primary ktosis.  the gluconeogenic effects of dexamethasone injection 2 mg/ml, when administered intramuscularyly, are generally noted within the first 5 to 12 hours.  when dexamethasone injection 2 mg/ml is used intravenously, the effects may be noted sooner.  blood sugar levels rise to normal levels repidly and genreally rise to above normal levels within 12 to 24 hours.  acetone bodies are reduce to normal concentrations usually witnin 24 hours.  th

United States - English - NLM (National Library of Medicine)

clipper distributing company, llc - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 2 mg in 1 ml - dexamethasone injection 2 mg/ml is indicated for the treatment of primary bovine ketosis and as an anti-inflammatory agent in the bovine and equine. as supportive therapy, dexamethasone injection 2 mg/ml may be used in the management of various rheumatic, allergic, dermatologic, and other diseases known to be responsive to anti-inflammatory corticosteroids. dexamethasone injection 2 mg/ml may be used intravenously as supportive therapy when an immediate hormonal response is required. bovine ketosis dexamethasone injection 2 mg/ml is offered for the treatment of primary ketosis. the gluconeogenic effects of dexamethasone injection 2 mg/ml, when administered intramuscularly, are generally noted within the first 6 to 12 hours. when dexamethasone injection 2 mg/ml is used intravenously, the effects may be noted sooner. blood sugar levels rise to normal levels rapidly and generally rise to above normal levels within 12 to 24 hours. acetone bodies are reduced to normal concentrations usually within 24 hours. the p

United States - English - NLM (National Library of Medicine)

vettek - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 2 mg in 1 ml - dexamethasone injection 2 mg/ml is indicated for the treatment of primary bovine ketosis and as an anti-inflammatory agent in the bovine and equine. as supportive therapy, dexamethasone injection 2 mg/ml may be used in the management of various rheumatic, allergic, dermatologic, and other diseases known to be responsive to anti-inflammatory corticosteroids. dexamethasone injection 2 mg/ml may be used intravenously as supportive therapy when an immediate hormonal response is required. bovine ketosis dexamethasone injection 2 mg/ml is offered for the treatment of primary ketosis. the gluconeogenic effects of dexamethasone injection 2 mg/ml, when administered intramuscularly, are generally noted within the first 6 to 12 hours. when dexamethasone injection 2 mg/ml is used intravenously, the effects may be noted sooner. blood sugar levels rise to normal levels rapidly and generally rise to above normal levels within 12 to 24 hours. acetone bodies are reduced to normal concentrations usually within 24 hours. the

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - dexamethasone, quantity: 0.5 mg/ml; framycetin sulfate, quantity: 5 mg/ml; gramicidin, quantity: 0.05 mg/ml - ear drops - excipient ingredients: phenethyl alcohol; polysorbate 80; citric acid monohydrate; sodium citrate dihydrate; lithium chloride; purified water; industrial methylated spirit; sodium hydroxide; hydrochloric acid - indications as at 22 march 1993: inflammatory and allergic conditions of the ear, e.g. otitis externa. eczema of the auditory meatus is often present and causes inflammation, exudation and pruritus, which are all rapidly relieved by dexamethasone. infection,often secondary to scratching, is generally due to staphylococci, e. coli, pseudomonas and proteus spp. which respond rapidly to framycetin.

Israel - English - Ministry of Health

mbi pharma ltd., israel - dexamethasone phosphate ( as sodium phosphate ) - solution for injection / infusion - dexamethasone phosphate ( as sodium phosphate ) 4 mg/ml - dexamethasone - dexamethasone kern pharma is indicated in the treatment of:• endocrine diseases such as nonsuppurative thyroiditis, hypercalcaemia associated with cancer and congenital adrenal hyperplasia.• allergy: severe or disabling allergic conditions resistant to conventional treatments, as in: bronchial asthma, contact or atopical dermatitis, seasonal or perennial allergic rhinitis, hypersensitivity reactions to drugs.• ophtalmic: serious inflammatory and allergic processes, acute and chronic, affecting the eyes, such as: iritis and iridocyclitis, chorioretinitis, choroiditis and diffuse posterior uveitis, optical neuritis, allergic conjunctivitis, allergic marginal corneal ulcers.• inflammatory bowel dis.: systemic treatment in exacerbations of ulcerative colitis and regional enteritis.• dermatological diseases (pemphigus, stevens johnson syndrome, exfoliative dermatitis, severe psoriasis and mycosis fungoides) • respiratory diseases (symptomatic sarcoidosis, berylliosis, loeffler's syndrome)• haematological: acquired )autoimmune( haemolytic anaemia, idiopathic thrombocytopenic purpura in adult, pure red cell aplasia• nephrotic syndrome of the idioplathic type or that due to lupus erythematosus• cerebral edema caused by brain tumor, neurosurgery, brain abscess, bacterial meningitis• collagen diseases: active rheumatoid arthritis with severe progressive course, fast destructive remitting forms and / or extra-articular manifestations, juvenile idiopathic arthritis with severe systemic-onset form (still's disease) or locally with no control, rheumatic fever with carditis, dermatomyositis, polymyositis, sle, temporal arteritis.• infectious diseases: bacterial meningitis – adjunct to antibiotics in suspected pneumococcal meningitis and tb meningitis. severe infectious diseases with toxic states (eg tuberculosis, typhoid, brucellosis;. only with simultaneous anti-infective therapy)• fetal lung maturation• chemotherapy – associated nausea and vomiting• multiple myeloma – part of chemotherapy protocols (eg vad)• prevention and treatment of acute mountain sickness/hace

United States - English - NLM (National Library of Medicine)

mwi/vetone - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 3 mg in 1 ml - indications and usage: dexamethasone-sp (dexamethasone sodium phosphate) is indicated as a rapid adrenal glucocorticoid and/or anti-inflammatory agent in horses. contraindications: do not use in viral infections. except when used for emergency therapy, dexamethasone sodium phosphate is contraindicated in animals with tuberculosis and chronic nephritis. existence of congestive heart failure, osteoporosis and diabetes are relative contraindications. in the presence of infection appropriate antibacterial agents should also be administered and should be continued for at least 3 days after discontinuance of the hormone and disappearance of all signs of infection.

Israel - English - Ministry of Health

mbi pharma ltd., israel - dexamethasone as sodium phosphate - solution for injection - dexamethasone as sodium phosphate 4 mg/ml - dexamethasone - dexamethasone kern pharma is indicated in the treatment of:• endocrine diseases such as nonsuppurative thyroiditis, hypercalcaemia associated with cancer and congenital adrenal hyperplasia.• allergy: severe or disabling allergic conditions resistant to conventional treatments, as in: bronchial asthma, contact or atopical dermatitis, seasonal or perennial allergic rhinitis, hypersensitivity reactions to drugs.• ophtalmic: serious inflammatory and allergic processes, acute and chronic, affecting the eyes, such as: iritis and iridocyclitis, chorioretinitis, choroiditis and diffuse posterior uveitis, optical neuritis, allergic conjunctivitis, allergic marginal corneal ulcers.• inflammatory bowel dis.: systemic treatment in exacerbations of ulcerative colitis and regional enteritis.• dermatological diseases (pemphigus, stevens johnson syndrome, exfoliative dermatitis, severe psoriasis and mycosis fungoides) • respiratory diseases (symptomatic sarcoidosis, berylliosis, loeffler's syndrome)• haematologica

United States - English - NLM (National Library of Medicine)

butler animal health supply - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone sodium phosphate 1 mg in 1 ml - for the treatment of the following conditions: ophthalmic: steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. otic: steroid responsive inflammatory conditions of the external auditory meatus, such as allergic otitis externa, selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. epithelial herpes simplex keratitis (dendritic keratitis). acute infectious stages of vaccinia, varicella and many other viral diseases of the cornea and conjunctiva. mycobacterial infection of the eye. funga